Amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil and what is the scope of patent protection?
Amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil
is the generic ingredient in two branded drugs marketed by Endo Operations, Teva Pharms Usa, Torrent, and Cosette, and is included in four NDAs. Additional information is available in the individual branded drug profile pages.Six suppliers are listed for this compound.
Summary for amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 4 |
| NDAs: | 4 |
| Finished Product Suppliers / Packagers: | 6 |
| Clinical Trials: | 4 |
| DailyMed Link: | amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil at DailyMed |
Recent Clinical Trials for amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Daiichi Sankyo Inc. | Phase 3 |
| Daiichi Sankyo, Inc. | Phase 3 |
| Daiichi Sankyo, Inc. | Phase 4 |
See all amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil clinical trials
Pharmacology for amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil
| Drug Class | Angiotensin 2 Receptor Blocker Calcium Channel Blocker Dihydropyridine Calcium Channel Blocker Thiazide Diuretic |
| Mechanism of Action | Angiotensin 2 Receptor Antagonists Calcium Channel Antagonists Cytochrome P450 3A Inhibitors |
| Physiological Effect | Increased Diuresis |
Anatomical Therapeutic Chemical (ATC) Classes for amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil
US Patents and Regulatory Information for amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Torrent | OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE | amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil | TABLET;ORAL | 203580-003 | Oct 26, 2016 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Torrent | OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE | amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil | TABLET;ORAL | 203580-004 | Oct 26, 2016 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Teva Pharms Usa | OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE | amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil | TABLET;ORAL | 202491-002 | Nov 3, 2016 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Cosette | TRIBENZOR | amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil | TABLET;ORAL | 200175-002 | Jul 23, 2010 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Cosette | TRIBENZOR | amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil | TABLET;ORAL | 200175-004 | Jul 23, 2010 | ⤷ Sign Up | ⤷ Sign Up |
| Cosette | TRIBENZOR | amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil | TABLET;ORAL | 200175-001 | Jul 23, 2010 | ⤷ Sign Up | ⤷ Sign Up |
| Cosette | TRIBENZOR | amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil | TABLET;ORAL | 200175-005 | Jul 23, 2010 | ⤷ Sign Up | ⤷ Sign Up |
| Cosette | TRIBENZOR | amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil | TABLET;ORAL | 200175-003 | Jul 23, 2010 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
